T cell avidity and tumor recognition: Implications and therapeutic strategies

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  McKee, Mark D ^a   Roszkowski, Jeffrey J ^a   Nishimura, Michael I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; EPITOPE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN RECEPTOR; SIGNAL PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANTIBODY COMBINING SITE; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; BINDING AFFINITY; CANCER; CANCER CELL; CANCER IMMUNOLOGY; CELL INTERACTION; CELLULAR IMMUNITY; CLINICAL TRIAL; EFFECTOR CELL; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN STRUCTURE; REVIEW; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 27344449925     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-35     Document Type: Review

References (160)

1. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA: The anti-idiotype vaccines for immunotherapy. Curr Opin Mol Ther 2001, 3:63-69.
2. Haigh PI, Difronzo LA, Gammon G, Morton DL: Vaccine therapy for patients with melanoma. Oncology (Huntingt) 1999, 13:1561-1574; discussion 1574 passim.
3. Nestle FO: Dendritic cell vaccination for cancer therapy. Oncogene 2000, 19:6673-6679.
4. Zeh HJ, III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. JImmunol 1999, 162:989.
5. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. JExpMed 1994, 179:1005.
6. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments]. JExpMed 1994, 180:35.
7. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 91:3515-3519.
8. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. ProcNatlAcadSciUSA 1994, 91:6458.
9. Robbins PF, el Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA: Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. JImmunol 1995, 154:5944.
10. Wolfel T, Hauer M, Klehmann E, Brichard. V, Ackermann B, Knuth A, Boon T, Meyer zum Buschenfelde KH: Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). IntJCancer 1993, 55:237.
11. Coulie PG: Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines? MolWedToday 1997, 3:261.
12. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380.
13. Boon T, Coulie PG, Van den EB: Tumor antigens recognized by T cells. Immuno/Today 1997, 18:267.
14. Chen YT, Old LJ: Cancer-testis antigens: targets for cancer immunotherapy [comment]. Cancer JSciAm 1999, 5:16.
15. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. ProcNatlAcadSciUSA 1997, 94:1914.
16. Jager D, Stockert E, Scanlan MJ, Gure AO, Jager E, Knuth A, Old LJ, Chen YT: Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 1999, 59:6197.
17. van der BP, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den EB, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643.
18. Van den EB, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T: A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. JExpMed 1995, 182:689.
19. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199.
20. Gaugler B, Van den EB, van der BP, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. JExpMed 1994, 179:921.
21. Van Den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T: A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription [see comments]. JExpMed 1999, 190:1793.
22. van der BP, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. EurJImmunol 1994, 24:3038.
23. Wallace LE, Rickinson AB, Rowe M, Epstein MA: Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982, 297:413.
24. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ: An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). JExpMed 1990, 171:345.
25. Kast WM, Brandt RM, Drijfhout JW, Melief CJ: Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. JImmunother 1993, 14:115.
26. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993, 151:225.
27. Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. HumImmunol 1997, 52:109.
28. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, et al: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. JImmunol 1999, 163:1037.
29. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumor antigen. ProcNatlAcadSciUSA 1995, 92:11993.
30. Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. EurJImmunol 1993, 23:2072.
31. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J: Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. JImmunol 1998, 160:328.
32. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998, 58:732.
33. Stauss HJ, Van Waes C, Fink MA, Starr B, Schreiber H: Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med 1986, 164:1516-1530.
34. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281.
35. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA: Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 2001, 62:1009-1030.
36. Huppa JB, Davis MM: T-cell-antigen recognition and the immunological synapse. Nature Reviews Immunology 2003, 3:973.
37. Snyder JT, Alexander-Miller MA, Berzofsky JA, Belyakov IM: Molecular mechanisms and biological significance of CTL avidity. Current Hiv Research 2003, 1:287.
38. Alexander-Miller MA, Leggatt GR, Berzofsky JA: Selective expansion of high- or low- avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. ProcNatlAcadSciUSA 1996, 93:4102.
39. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA: Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. JExpMed 1996, 184:485.
40. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA: Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. JImmunother 1999, 22:288.
41. Sette A, Fikes J: Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Current Opinion in Immunology 2003, 15:461.
42. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ: Shared T-Cell Epitopes in Epithelial Tumors. Cellular Immunology 1995, 164:279.
43. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R: Identification of HER2/neuderived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. IntJCancer 1998, 78:202.
44. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 1994, 54:1071.
45. Zaks TZ, Rosenberg SA: Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998, 58:4902.
46. Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. ClinCancer Res 2002, 8:1014.
47. Kerry SE, Buslepp J, Cramer LA, Maile R, Hensley LL, Nielsen AI, Kavathas P, Vilen BJ, Collins EJ, Frelinger JA: Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. JImmunol 2003, 171:4493.
48. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Lienard D, Speiser D, Guillaume P, Batard P, et al: Heterogeneous T-cell response to MAGE-A10(254-262): High avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Research 2001, 61:5850.
49. Derby MA, Wang J, Margulies DH, Berzofsky JA: Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. IntImmunol 2001, 13:817.
50. Dutoit V, Guillaume P, Cerottini JC, Romero P, Valmori D: Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. European Journal of Immunology 2002, 32:3285.
51. Cawthon AG, Lu HP, Alexander-Miller MA: Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: Correlation with CD8 alpha beta versus CD8 alpha alpha expression. Journal of Immunology 2001, 167:2577.
52. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, et al: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001, 24:363-373.
53. Dudley ME, Ngo LT, Westwood J, Wunderlich JR, Rosenberg SA: T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J 2000, 6:69.
54. Denkberg G, Klechevsky E, Reiter Y: Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: Probing with TCR-like recombinant antibodies. Journal of Immunology 2002, 169:4399.
55. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, Nishimura MI: Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995, 55:748.
56. Roszkowski JJ, Yu DC, McKee MD, Cole DJ, McKee MD, Nishimura MI: CD8 Independent Tumor Cell Recognition is a Property of the T Cell Receptor and not the T Cell. Submitted, JImmunol 2002.
57. Morgan RA, Dudley ME, Yu YYL, Zheng ZL, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA: High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Journal of Immunology 2003, 171:3287.
58. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992, 258:1795.
59. Boniface JJ, Davis MM: T-cell recognition of antigen. A process controlled by transient intermolecular interactions. AnnNYAcadSci 1995, 766:62.
60. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC: Regulation of T cell receptor CD3 chain expression by L-arginine. Journal of Biological Chemistry 2002, 277:21123.
61. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC: L-arginine consumption by macrophages modulates the expression of CD3 xi chain in T lymphocytes. Journal of Immunology 2003, 171:1232.
62. Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L, Longo DL: Sequential development of structural and functional alterations in T cells from tumor-bearing mice. Journal of Immunology 1997, 158:5292.
63. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R: Decreased expression of the signal-transducing zeta chains in tumor- infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53:5610.
64. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, Oshea JJ, Kudoh S, Klein E, et al: Loss of T-Cell Receptor Zeta-Chain and P56(Lck) in T-Cells Infiltrating Human Renal-Cell Carcinoma. Cancer Research 1993, 53:5613.
65. Fu EJ, Arca MJ, Hain JM, Krinock R, Rado J, Cameron MJ, Chang AE, Sondak VK: Tumor-induced suppression of antitumor reactivity and depression of TCR zeta expression in tumor-draining lymph node lymphocytes: Possible relationship to the Th2 pathway. Journal of Immunotherapy 1997, 20:111.
66. Noda S, Nagatanarumiya T, Kosugi A, Narumiya S, Ra C, Fujiwara H, Hamaoka T: Do Structural-Changes of T-Cell Receptor Complex Occur in Tumor-Bearing State. Japanese Journal of Cancer Research 1995, 86:383.
67. Rabinowich H, Suminami Y, Reichert TE, CrowleyNowick P, Bell M, Edwards R, Whitesrde TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. International Journal of Cancer 1996, 68:276.
68. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. EurJImmunol 1996, 26:1308.
69. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 2002, 101:151.
70. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van Den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine 2003, 9:1269.
71. Salazar-Fontana LI, Bierer BE: T-lymphocyte coactivator molecules. Current Opinion in Hematology 2001, 8:5.
72. Norment AM, Littman DR: A 2Nd Subunit of Cd8 Is Expressed in Human T-Cells. Embo Journal 1988, 7:3433.
73. Disanto JP, Knowles RW, Flomenberg N: The Human Lyt-3 Molecule Requires Cd8 for Cell-Surface Expression. Embo Journal 1988, 7:3465.
74. Moebius U, Kober G, Griscelli AL, Hercend T, Meuer SC: Expression of Different Cd8 Isoforms on Distinct Human Lymphocyte Subpopulations. European Journal of Immunology 1991, 21:1793.
75. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. NatMed 1998, 4:321.
76. Staib L, Birebent B, Somasundaram R, Purev E, Braumuller H, Leeser C, Kuttner N, Li W, Zhu D, Diao J, et al: Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. IntJCancer 2001, 92:79.
77. Cole DJ, Wilson MC, Baron PL, O'Brien P, Reed C, Tsang KY, Schlom J: Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. HumGene Ther 1996, 7:1381.
78. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, et al: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. ClinCancer Res 2000, 6:1632.
79. Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CJ, Schlom J: A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. JImmunother 1999, 22:155.
80. Correa I, Hentzel IR: On solvability of noncommutative power-associative nilalgebras. Journal of Algebra 2001, 240:98.
81. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999, 39:54.
82. Loftus DJ, Squarcina P, Nielsen MB, Geisler C, Castelli C, Odum N, Appella E, Parmiani G, Rivoltini L: Peptides derived from self-proteins as partial agonists and antagonists of human CD8(+) T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Research 1998, 58:2433.
83. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. JImmunol 1996, 157:2539.
84. Vertuani S, Sette A, Sidney J, Southwood S, Fikes J, Keogh E, Lindencrona JA, Ishioka G, Levitskaya J, Kiessling R: Improved immunogenicity of an immunodominant epitope of the Her-2/neu protooncogene by alterations of MHC contact residues. Journal of Immunology 2004, 172:3501.
85. Bownds S, Tong-On P, Rosenberg SA, Parkhurst M: Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. JImmunother 2001, 24:1.
86. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Lienard D, Cerundolo V, Cerottini JC, Romero P: Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. Journal of Immunology 2000, 164:1125.
87. Kittlesen DJ, Thompson LW, Gulden PH, Skipper JCA, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL: Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998). Journal of Immunology 1999, 162:3106.
88. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH: Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. JExpMed 2000, 191:1221.
89. Disis ML, Shiota FM, Cheever MA: Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology 1998, 93:192.
90. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001, 167:7150-7156.
91. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000, 13:529.
92. Zaremba S, Barzaga E, Zhu MZ, Soares N, Tsang KY, Schlom J: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research 1997, 57:4570.
93. Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG: Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. Journal of Immunology 2002, 169:3545
94. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli F, Parmiani G: A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 1999, 59:301.
95. Fong L, Hou YF, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:8809.
96. Tangri S, Ishioka GY, Huang XQ, Sidney J, Southwood S, Fikes S, Sette A: Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. Journal of Experimental Medicine 2001, 194:833.
97. Kaye J, Vasquez NJ, Hedrick SM: Involvement of the same region of the T cell antigen receptor in thymic selection and foreign peptide recognition. JImmunol 1992, 148:3342.
98. Sorger SB, Paterson Y, Fink PJ, Hedrick SM: T cell receptor junctional regions and the MHC molecule affect the recognition of antigenic peptides by T cell clones. JImmunol 1990, 144:1127.
99. Sensi M, Parmiani G: Analysis of TCR usage in human tumors: a new tool for assessing tumor- specific immune responses. ImmunolToday 1995, 16:588.
100. Nitta T, Oksenberg JR, Rao NA, Steinman L: Predominant expression of T cell receptor V alpha 7 in tumor- infiltrating lymphocytes of uveal melanoma. Science 1990, 249:672.
101. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T: Analysis of T-Cell Receptor Variability in Tumor-Infiltrating Lymphocytes from A Human Regressive Melanoma - Evidence for Insitu T-Cell Clonal Expansion. Journal of Clinical Investigation 1993, 91:1183.
102. Straten PT, Scholler J, Houjensen K, Zeuthen J: Preferential Usage of T-Cell Receptor-Alpha-Beta Variable Regions Among Tumor-Infiltrating Lymphocytes in Primary Human-Malignant Melanomas. International Journal of Cancer 1994, 56:78.
103. Weidmann E, Logan TF, Yasumura S, Kirkwood JM, Trucco M, Whiteside TL: Evidence for Oligoclonal T-Cell Response in A Metastasis of Renal-Cell Carcinoma Responding to Vaccination with Autologous Tumor-Cells and Transfer of In-Vitro-Sensitized Vaccine-Draining LymphNode Lymphocytes. Cancer Research 1993, 53:4745.
104. Bennett WT, Pandolfi F, Grove BH, Hawes GE, Boyle LA, Kradin RL, Kurnick JT: Dominant Rearrangements Among Human Tumor-Infiltrating Lymphocytes - Analysis of T-Cells Derived from 32 Patients with Melanoma, Lung, and Renal-Cell Carcinoma. Cancer 1992, 69:2379.
105. Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian S, Jennings C, Eliyahu S, Rosenberg SA, Nishimura MI: Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope [published erratum appears in Cancer Res 1994 Nov 15;54(22):6014]. Cancer Res 1994, 54:5265.
106. Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA: T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines. J Immunother 1998, 21:352-362.
107. Nishimura MI, Kawakami Y, Charmley P, O'Neil B, Shilyansky J, Yannelli JR, Rosenberg SA, Hood L: T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. JImmunotherEmphasisTumor Immunol 1994, 16:85.
108. Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA: T-cell receptor usage by melanoma-specific clonal, and highly oligoclonal tumor-infiltrating lymphocyte lines. ProcNatlAcadSciUSA 1994, 91:2829.
109. Romero P, Pannetier C, Herman J, Jongeneel CV, Cerottini JC, Coulie PG: Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A.1 JExpMed 1995, 182:1019.
110. Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, et al: Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. Journal of Immunology 2003, 170:5103.
111. Ferradini L, Roman-Roman S, Azocar J, Avril MF, Viel S, Triebel F, Hercend T: Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res 1992, 52:4649.
112. Albertini MR, Nicklas JA, Chastenay BF, Hunter TC, Albertini RJ, Clark SS, Hank JA, Sondel PM: Analysis of T-Cell Receptor Beta- and Gamma-Genes from Peripheral-Blood, Regional Lymph-Node and Tumor-Infiltrating Lymphocyte Clones from Melanoma Patients. Cancer Immunology Immunotherapy 1991, 32:325.
113. Dufour E, Carcelain G, Gaudin C, Flament C, Avril MF, Faure F: Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. JImmunol 1997, 158:3787.
114. Maeurer MJ, Martin DM, Storkus WJ, Lotze MT: Tcr Usage in Ctls Recognizing Melanoma Melanocyte Antigens. Immunology Today 1995, 16:603.
115. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone. JExpMed 1993, 178:1231.
116. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T: Cytotoxic T-lymphocyte clones from different patients display limited T- cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. ProcNatlAcadSciUSA 1995,92:5674.
117. Jorgensen JL, Esser U, Destgroth BF, Reay PA, Davis MM: Mapping T-Cell Receptor Peptide Contacts by Variant Peptide Immunization of Single-Chain Transgenics. Nature 1992, 355:224.
118. Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlich J, Rosenberg SA, Nishimura MI: Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. JImmunol 1999, 162:1749.
119. Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H, Steinmetz M: Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 1986, 320:232-238.
120. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. JExpMed 1994, 180:347.
121. Aarnoudse CA, Kruse M, Konopitzky R, Brouwenstijn N, Schrier PI: TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. IntJCancer 2002, 99:7.
122. Calogero A, Hospers GA, Kruse KM, Schrier PI, Mulder NH, Hooijberg E, de Leij LF: Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res 2000, 20:1793-1799.
123. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol 1999, 163:507-513.
124. Clay TM, Custer MC, Spiess PJ, Nishimura MI: Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. Pathol Oncol Res 1999, 5:3-15.
125. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. MolCell Biol 1990, 10:4239.
126. Schaft N, Willemsen RA, de Vries J, Lankiewicz B, Essers BW, Gratama JW, Figdor CG, Bolhuis RL, Debets R, Adema GJ: Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 2003, 170:2186.
127. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI: Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. ClinImmunol 2001, 98:220.
128. Roszkowski JJ, Eiben GE, Kast WM, Yee C, Van Besien K, Nishimura MI: Simultaneous generation of CD8+ and CD4+ melanoma reactive T cells by retroviral mediated transfer of a single T cell receptor. vol. 65(4); 2005.
129. Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI: CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol 2003, 170:2582-2589.
130. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RL, Melief CJ, Huber C, et al: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001, 2:962-970.
131. Heemskerk MH, Hoogeboom M, Hagedoom R, Kester MG, Willemze R, Falkenburg JH: Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J ExpMed 2004, 199:885.
132. Langerman A, Callender GG, Nishimura MI: Retroviral transduction of peptide stimulated T cells can generate dual T cell receptor-expressing (bifunctional) T cells reactive with two defined antigens. JTrans/Med 2004, 2:42.
133. Blichfeldt E, Munthe LA, Rotnes JS, Bogen B: Dual T cell receptor T cells have a decreased sensitivity to physiological ligands due to reduced density of each T cell receptor. EurfImmunol 1996, 26:2876.
134. Munthe LA, Blichfeldt E, Sollien A, Dembic Z, Bogen B: T cells with two Terbeta chains and reactivity to both MHC/idiotypic peptide and superantigen. Cell Immunol 1996, 170:283.
135. Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL: Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000, 7:1369.
136. Vagner S, Galy B, Pyronnet S: Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2001, 2:893.
137. Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, Naldini L, Bonini C: Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003, 102:497-505.
138. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Katoh H, Takeshima T, Nishimura T: Generation and targeting of human tumor-specific Tcl and Thl cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 2004, 64:1490.
139. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL: Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood 2002, 99:2342.
140. Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye Z, Pardoll DM, Jaffee EM, Cheng L: Lentivirus-mediated gene transfer and expression in
141. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989, 86:10024-10028.
142. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z: Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993, 151:6577-6582.
143. Muniappan A, Banapour B, Lebkowski J, Talib S: Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther 2000, 7:128-134.
144. Altenschmidt U, Klundt E, Groner B: Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997, 159:5509-5515.
145. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995, 55:3369-3373.
146. Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG, Eshhar Z: Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther 1998, 5:401-407.
147. Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P: Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000, 11:2377-2387.
148. Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL: Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 1996, 157:836-843.
149. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP: Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000, 2:449-459.
150. Paul S, Bizouarne N, Dott K, Ruet L, Dufour P, Acres RB, Kieny MP: Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000, 7:615-623.
151. Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P: Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000, 7:284-291.
152. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ: Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. Eur J Immunol 1998, 28:1663-1672.
153. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, Junghans RP: Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res 1999, 5:3928-3941.
154. Schirrmann T, Pecher G: Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002, 9:390-398.
155. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK: Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 2001, 166:182-187.
156. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002, 20:70-75.
157. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002, 100:3155-3163.
158. Finney HM, Lawson AD, Bebbington CR, Weir AN: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998, 161:2791-2797.
159. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H: Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001, 167:6123-6131.
160. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK: Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002, 169:5780-5786.